KRAS and cancer: Recent studies in mutant KRAS- or BRAF-driven mouse models of cancer, such as pancreatic ductal adenocarcinoma cancer (PDAC), demonstrated synergistic antitumor activity with dual autophagy inhibition and mitogen-activated protein kinase kinase (MEK) or mitogen-activated protein kinase (ERK) inhibitors [28,34].